Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Critical Reviews in Oncology/Hematology|August 24, 2005
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinomaJ Atzpodien, T Wandert, M ReitzBritish Journal of Cancer|February 6, 2003
Metastatic renal carcinoma comprehensive prognostic systemJ Atzpodien, P Royston, T Wandert, et al.British Journal of Cancer|July 3, 2003
Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcomeJ Atzpodien, Th Küchler, T Wandert, et al.British Journal of Cancer|March 31, 1999
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinomaF Wittke, R Hoffmann, J Buer, et al.British Journal of Cancer|March 10, 2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, E Schmitt, U Gertenbach, et al.British Journal of Cancer|November 17, 2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trialJ Atzpodien, H Kirchner, H J Illiger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Jonas, et al.Pageof 1